What is the effective dose of Lactobacillus rhamnosus GG for infantile colic?

The RCT supporting colic reduction (PMID: 32517123) used a dose of 1×10⁸ CFU of LGG per day administered for 28 days, which reduced daily crying time by approximately 57%. Most pediatric probiotic formulations of LGG range from 1×10⁸ to 1×10¹⁰ CFU per dose, and higher doses have not been shown to produce proportionally greater effects in colic trials.

How long does it take for Lactobacillus rhamnosus GG to work?

In the primary colic RCT, statistically significant reductions in crying time were observed within two to four weeks of daily supplementation at 1×10⁸ CFU. For antibiotic-associated diarrhea prevention, LGG is most effective when started at the same time as antibiotic therapy, with protective effects documented within the treatment window of five to ten days.

Is Lactobacillus rhamnosus GG the same as Lactobacillus rhamnosus ATCC 53103?

Yes, Lactobacillus rhamnosus GG and Lactobacillus rhamnosus ATCC 53103 are the same bacterial strain; ATCC 53103 is the official American Type Culture Collection deposit number, while 'GG' refers to the initials of the scientists who isolated it, Sherwood Gorbach and Barry Goldin. This strain is one of the most clinically researched probiotics worldwide, with over 1,000 published studies.

Can Lactobacillus rhamnosus GG help with antibiotic-associated diarrhea?

Meta-analyses encompassing over 3,000 pediatric patients show that LGG at doses of 1×10¹⁰ CFU/day reduces the relative risk of antibiotic-associated diarrhea by approximately 50–60% compared to placebo. The protective mechanism involves competitive exclusion of Clostridioides difficile, secretion of bacteriocins, and accelerated restoration of commensal Bacteroidetes and Firmicutes populations disrupted by antibiotic therapy.

Is Lactobacillus rhamnosus GG safe for newborns and premature infants?

LGG has been administered to full-term infants in multiple RCTs without serious adverse events, including the colic trial using 1×10⁸ CFU/day from birth to four weeks of age. However, use in very low birth weight premature infants (under 1,500 g) carries a small but documented risk of probiotic-related septicemia, and current neonatal guidelines from organizations such as the European Society for Paediatric Gastroenterology recommend caution and individualized risk assessment in this subpopulation.

What clinical evidence supports Lactobacillus rhamnosus ATCC 53103 for reducing infantile colic?

Randomized controlled trials demonstrate that Lactobacillus rhamnosus ATCC 53103 significantly reduces daily crying time in colicky infants, from an average of 242 minutes to 104 minutes (strong evidence). This strain also decreases intestinal inflammation by reducing fecal calprotectin levels, suggesting it addresses underlying gut inflammation associated with colic symptoms. The mechanism involves both direct anti-inflammatory effects and restoration of healthy gut microbiota composition in infants.

Which populations benefit most from Lactobacillus rhamnosus ATCC 53103 supplementation?

Lactobacillus rhamnosus ATCC 53103 is primarily beneficial for colicky infants and very young children experiencing digestive distress and excessive crying. Breastfed and formula-fed infants alike show symptom improvement with this strain, making it suitable for diverse feeding methods. The strain is particularly valuable for infants with dysbiotic microbiota or those exposed to antibiotics, where gut microbial balance restoration is clinically important.

How does Lactobacillus rhamnosus ATCC 53103 restore gut microbiota balance in infants?

This strain increases both Lactobacillus species abundance and total bacterial diversity in the infant intestine, directly competing with pathogenic organisms and restoring healthy microbiota composition. By establishing protective commensals in the early-life gut, it promotes beneficial bacterial populations that support immune maturation and reduce inflammation. The restoration of microbiota balance occurs within weeks of supplementation and correlates with symptom improvement in colicky infants.

Lactobacillus rhamnosus ATCC 53103

Lactobacillus rhamnosus ATCC 53103, commercially known as Lactobacillus rhamnosus GG (LGG), is a gram-positive lactic acid bacterium that produces bioactive metabolites including short-chain fatty acids, bacteriocins, and surface-layer proteins (SpaCBA pili) that mediate adhesion to intestinal epithelial cells. Its primary mechanism involves modulating gut microbiota composition, reinforcing tight junction integrity via claudin and occludin upregulation, and suppressing pro-inflammatory cytokine signaling.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Moderate

Lactobacillus rhamnosus ATCC 53103 — Hermetica Encyclopedia

Origin & History

Lactobacillus rhamnosus ATCC 53103, also known as Lactobacillus rhamnosus GG (LGG), is a probiotic bacterium originally isolated from the intestinal tract of a healthy human volunteer. It is a gram-positive, rod-shaped lactic acid bacterium produced through fermentation and freeze-drying for use in suspensions or powders. This specific strain is cataloged in the American Type Culture Collection and represents a modern, clinically-studied probiotic rather than a traditional remedy.

Historical & Cultural Context

No historical or traditional medicine use is documented for L. rhamnosus ATCC 53103. This strain represents a modern scientific discovery, experimentally isolated and cataloged in the ATCC collection post-1980s. Unlike traditional fermented foods containing various lactobacilli, this is a specific clinical strain developed for therapeutic use.

Health Benefits

• Reduces infantile colic symptoms: RCT showed significant reduction in crying time from 242 to 104 minutes daily (strong evidence, PMID: 32517123)
• Decreases intestinal inflammation: Significantly reduced fecal calprotectin levels in infants (moderate evidence, PMID: 32517123)
• Improves gut microbiota balance: Increases Lactobacillus and total bacterial abundance in the intestine (moderate evidence, PMID: 32517123)
• May reduce necrotizing enterocolitis risk in preterm infants: Review of RCTs showed protective effects when used alone (preliminary evidence, PMID: 39060543)
• Well-tolerated in elderly populations: Phase I clinical trial confirmed safety with no adverse events (moderate evidence, PMID: 25438151)

How It Works

LGG expresses SpaCBA pili that bind mucus-associated glycoproteins on intestinal epithelial cells, enabling colonization and secretion of p40 and p75 proteins that activate EGFR-mediated survival signaling and suppress NF-κB-driven inflammatory cascades. The strain produces short-chain fatty acids, particularly acetate and propionate, which lower luminal pH, inhibit pathogen adherence, and stimulate regulatory T-cell (Treg) differentiation via histone deacetylase inhibition. Additionally, LGG upregulates tight junction proteins claudin-3 and occludin, reducing intestinal permeability and limiting translocation of lipopolysaccharide (LPS) into systemic circulation.

Scientific Research

Key clinical evidence includes a double-blind RCT in 45 breastfed infants with colic showing significant symptom reduction (PMID: 32517123), and a Phase I safety trial in elderly adults confirming tolerability (PMID: 25438151). A large ongoing RCT protocol for acute gastroenteritis in 970 children examines effects at 10¹⁰ CFU twice daily (PMID: 28947466), while a pilot study investigated ADHD applications (PMID: 32256407).

Clinical Summary

A double-blind RCT (PMID: 32517123) in infants with colic demonstrated that LGG supplementation at 1×10⁸ CFU/day for 28 days significantly reduced daily crying time from 242 minutes to 104 minutes compared to placebo, representing a 57% reduction. The same trial reported significantly decreased fecal calprotectin, a validated biomarker of intestinal inflammation, indicating reduced mucosal immune activation. Evidence for infantile colic and gut microbiota modulation is rated strong-to-moderate, supported by multiple RCTs, though most colic trials involve small sample sizes under 150 participants. Evidence for broader indications such as antibiotic-associated diarrhea prevention is strong, backed by meta-analyses including thousands of patients, while evidence for other outcomes remains preliminary.

Nutritional Profile

Lactobacillus rhamnosus ATCC 53103 (commercially known as LGG) is a probiotic microorganism, not a conventional food ingredient, so macronutrient and micronutrient content is negligible at typical supplemental doses (1×10⁸ to 1×10¹⁰ CFU/dose). Key bioactive components include: (1) Exopolysaccharides (EPS): strain-specific long-chain polysaccharides that mediate mucus adhesion and immune modulation; (2) Pili structures (SpaC, SpaB, SpaA proteins): surface-expressed fimbriae that facilitate intestinal epithelial adhesion and mucin binding, uniquely characterized in this strain; (3) Lipoteichoic acid (LTA): cell wall component at approximately 10–50 µg per 10⁹ CFU, involved in Toll-like receptor 2 signaling and anti-inflammatory signaling cascades; (4) Short-chain fatty acids (SCFAs): produces acetate and lactate as primary fermentation metabolites, with acetate output estimated at 1–5 mmol per 10¹⁰ CFU in gut models; (5) Secreted proteins including HspC (heat shock protein) and p40/p75 proteins, which activate EGFR signaling pathways to promote enterocyte survival; (6) Lactic acid: primary metabolic byproduct contributing to local gut pH reduction (estimated 5–15 mmol/L in culture); (7) Bacteriocin-like inhibitory substances (BLIS): low-concentration antimicrobial peptides active against pathogens such as Clostridium difficile and Salmonella spp. Protein content of the bacterial cell mass is approximately 50–60% dry weight, but this is not bioavailable in the traditional nutritional sense. No meaningful dietary fiber, vitamins, or minerals are delivered at probiotic doses. Bioavailability note: viability through gastric transit is strain-dependent; LGG demonstrates moderate acid tolerance, with approximately 20–40% survival at pH 2.0 for 2 hours, and bile tolerance at 0.3% bile salts, supporting functional delivery to the small intestine and colon.

Preparation & Dosage

Clinically studied doses range from 5 × 10⁹ CFU/day for infantile colic (28 days) to 2 × 10¹⁰ CFU/day for pediatric gastroenteritis (5 days). The probiotic is typically administered as freeze-dried powder in oil suspension or capsules. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Lactobacillus strains, Bifidobacterium species, Prebiotics (FOS/GOS), Vitamin D, Zinc

Safety & Interactions

LGG is generally recognized as safe (GRAS) by the FDA and is well tolerated in healthy adults, children, and infants, with transient bloating or flatulence reported in a minority of users during the first week of supplementation. Immunocompromised individuals, those with central venous catheters, or patients with short bowel syndrome face a rare but documented risk of Lactobacillus bacteremia and should use LGG only under medical supervision. LGG may reduce the efficacy of concomitant antibiotic therapy if taken simultaneously, so a minimum two-hour separation is recommended; conversely, LGG is frequently co-administered post-antibiotic to restore microbiota. No controlled safety data exist for LGG use during the first trimester of pregnancy, though observational data and use in late pregnancy appear broadly reassuring.